Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson’s disease dementia

Gu, Chao; Shen, Ting; An, Hong‐Mei; Yuan, Can-Xing; Jie, Zhou; Ye, Qing; Liu, Tao; Wang, Xiuwei; Zhang, Tianli

doi:10.1016/j.neulet.2015.08.019

Cited by 18 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An exploratory study of 9 patients was conducted to study the effects of donepezil in PD patients with dementia, especially the effects of dose escalation [ 33 ], and the results showed that certain dose escalations of donepezil are useful for patients in the long term. In addition, the results of a randomized double-blind study showed that the combined use of donepezil and Di-Huang-Yi-Zhi is very effective in treating PD dementia, with a possible underlying reason that problems with the cholinergic system were ameliorated by such a combination therapy [ 34 ].…”

Section: Resultsmentioning

confidence: 99%

Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease

Zhao¹,

Yang²

2018

J Med Internet Res

View full text Add to dashboard Cite

BackgroundDue to the high cost and low success rate in new drug development, systematic drug repositioning methods are exploited to find new indications for existing drugs.ObjectiveWe sought to propose a new computational drug repositioning method to identify repositioning drugs for Parkinson disease (PD).MethodsWe developed a novel heterogeneous network mining repositioning method that constructed a 3-layer network of disease, drug, and adverse drug reaction and involved user-generated data from online health communities to identify potential candidate drugs for PD.ResultsWe identified 44 non-Parkinson drugs by using the proposed approach, with data collected from both pharmaceutical databases and online health communities. Based on the further literature analysis, we found literature evidence for 28 drugs.ConclusionsIn summary, the proposed heterogeneous network mining repositioning approach is promising for identifying repositioning candidates for PD. It shows that adverse drug reactions are potential intermediaries to reveal relationships between disease and drug.

show abstract

Section: Resultsmentioning

confidence: 99%

Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease

Zhao¹,

Yang²

2018

J Med Internet Res

View full text Add to dashboard Cite

show abstract

“…Many studies have shown that the increase of Hcy level in peripheral blood of AD patients was considered to be a risk factor for the occurrence of AD ( 44 , 45 ). Research by Gu et al ( 46 ) showed that Dihuang Yizhi recipe combined with donepezil hydrochloride could significantly improve ADL score, MMSE score and MoCA score of dementia patients with Parkinson's disease. Moreover, it was reported that donepezil could significantly reduce the serum Hcy level of AD patients and had good therapeutic effect ( 47 ).…”

Section: Discussionmentioning

confidence: 99%

Expression of miR‑28‑3p in patients with Alzheimer's disease before and after treatment and its clinical value

2020

View full text Add to dashboard Cite

Expression of miR-28-3p in patients with Alzheimer's disease (AD) before and after treatment and clinical value of miR-28-3p were determined. There were three groups: 68 AD patients treated with donepezil combined with basic therapy in The People's Hospital of Shouguang collected as an AD group, 70 patients with mild cognitive impairment (MCI) as an MCI group, and 75 healthy people as a normal group. Serum miR-28-3p was detected by qRT-PCR. The Montreal cognitive assessment scale (MoCA), mini mental state examination scale (MMSE), activities of daily living scale (ADL) and homocysteine (Hcy) were adopted to assess patients before and after treatment. miR-28-3p in normal group was significantly lower than that in other two groups, and miR-28-3p in MCI group was significantly lower than that in AD group (P<0.001). miR-28-3p correlated with the course and severity of patients. miR-28-3p in AD group after treatment was significantly lower than that before treatment (P<0.001). ADL and Hcy of AD patients after treatment were significantly lower than before treatment (P<0.05), and MMSE and MoCA after treatment were significantly higher than before treatment (P<0.05). Before and after treatment, miR-28-3p was significantly positively correlated with ADL score and Hcy level, but negatively correlated with MMSE score and MoCA score. Analysis of the working characteristic curve of the patients indicated that miR-28-3p can be used for diagnosis of AD patients. Donepezil therapy may reduce miR-28-3p level to alleviate the symptoms of AD patients, and miR-28-3p level can be used as an early diagnosis and prognosis evaluation of AD patients.

show abstract

“…An exploratory study of nine patients were conducted to study the effects of donepezil in PD patients with dementia, especially the effects of dose escalation [27] and the results showed that certain amount of dose escalation of donepezil is useful for patients in the long term. In addition, the results of a randomized and double-blind study showed that the combined use of donepezil and Di-Huang-Yi-Zhi (DHYZ) is very effective on treating PD dementia, with a possible underlying reason that the cholinergic system was ameliorated by such a combination therapy [28].…”

Section: Medication For Alzheimermentioning

confidence: 99%

Drug Repositioning for Parkinson�s Disease Based on Adverse Drug Reactions Detected from Social Media (Preprint)

Zhao¹,

Yang²

2017

Preprint

View full text Add to dashboard Cite

show abstract

Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson’s disease dementia

Cited by 18 publications

References 24 publications

Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease

Drug Repositioning to Accelerate Drug Development Using Social Media Data: Computational Study on Parkinson Disease

Expression of miR‑28‑3p in patients with Alzheimer's disease before and after treatment and its clinical value

Drug Repositioning for Parkinson�s Disease Based on Adverse Drug Reactions Detected from Social Media (Preprint)

Contact Info

Product

Resources

About